APO RESEARCH · REPORT
Cyazofamid
Cyazofamid is a kind of sulfamethoxazole fungicides with light yellow solid powder, which has high biological activity against the fungi.
Product & engineering
Understand the product.
Cyazofamid is a kind of sulfamethoxazole fungicides with light yellow solid powder, which has high biological activity against the fungi.
Cyazofamid, discovered and developed by ISHIHARA SANGYO KAISHA on the global basis after first launched in 2001, is often used in downy mildew, oomycetes diseases, pepper and others.
Cyazofamid has good toxicological, environmental and ecotoxicological profiles.
In this report, we count technical grade and chapter 6 displays the preparation content.
Selected research
Industry Research
Cyazofamid Industry Research Report 2026
Market perspective
Cyazofamid is a kind of sulfamethoxazole fungicides with light yellow solid powder, which has high biological activity against the fungi.
Cyazofamid, discovered and developed by ISHIHARA SANGYO KAISHA on the global basis after first launched in 2001, is often used in downy mildew, oomycetes diseases, pepper and others.
Cyazofamid has good toxicological, environmental and ecotoxicological profiles.
Read the full market overview
In this report, we count technical grade and chapter 6 displays the preparation content.
ISHIHARA SANGYO KAISHA is the largest manufacturer in the global market, with the share of 81%.
The consumption shares of Japan, China, North America and Europe were 42%, 21%, 17% and 11%. Japan is the main import region and other countries need to import from Japan.
Report Scope
This report quantifies the global Cyazofamid market in revenue (US$ million) and, where applicable, sales volume (kt), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/kt) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Cyazofamid.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cyazofamid Market by Company
ISHIHARA SANGYO KAISHA
Rudong Zhongyi
Cyazofamid Segment by Type
Agriculture Grade
Others
Cyazofamid Segment by Application
Downy Mildew
Oomycetes Diseases
Others
Cyazofamid Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyazofamid market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cyazofamid and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyazofamid.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cyazofamid manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cyazofamid by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cyazofamid in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Agriculture Grade
- Others
Applications
- Downy Mildew
- Oomycetes Diseases
- Others
Companies covered
- ISHIHARA SANGYO KAISHA
- Rudong Zhongyi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cyazofamid by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Agriculture Grade
- 2.2.3 Others
- 2.3 Cyazofamid by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Downy Mildew
- 2.3.3 Oomycetes Diseases
- 2.3.4 Others
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Cyazofamid Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Cyazofamid Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Cyazofamid Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Cyazofamid Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cyazofamid Production by Manufacturers (2021-2026)
- 3.2 Global Cyazofamid Production Value by Manufacturers (2021-2026)
- 3.3 Global Cyazofamid Average Price by Manufacturers (2021-2026)
- 3.4 Global Cyazofamid Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Cyazofamid Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Cyazofamid Manufacturers, Product Type & Application
- 3.7 Global Cyazofamid Manufacturers Established Date
- 3.8 Global Cyazofamid Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ISHIHARA SANGYO KAISHA
- 4.1.1 ISHIHARA SANGYO KAISHA Cyazofamid Company Information
- 4.1.2 ISHIHARA SANGYO KAISHA Cyazofamid Business Overview
- 4.1.3 ISHIHARA SANGYO KAISHA Cyazofamid Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 ISHIHARA SANGYO KAISHA Product Portfolio
- 4.1.5 ISHIHARA SANGYO KAISHA Recent Developments
- 4.2 Rudong Zhongyi
- 4.2.1 Rudong Zhongyi Cyazofamid Company Information
- 4.2.2 Rudong Zhongyi Cyazofamid Business Overview
- 4.2.3 Rudong Zhongyi Cyazofamid Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 Rudong Zhongyi Product Portfolio
- 4.2.5 Rudong Zhongyi Recent Developments
5 Global Cyazofamid Production by Region
- 5.1 Global Cyazofamid Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cyazofamid Production by Region: 2021-2032
- 5.2.1 Global Cyazofamid Production by Region: 2021-2026
- 5.2.2 Global Cyazofamid Production Forecast by Region (2027-2032)
- 5.3 Global Cyazofamid Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Cyazofamid Production Value by Region: 2021-2032
- 5.4.1 Global Cyazofamid Production Value by Region: 2021-2026
- 5.4.2 Global Cyazofamid Production Value Forecast by Region (2027-2032)
- 5.5 Global Cyazofamid Market Price Analysis by Region (2021-2026)
- 5.6 Global Cyazofamid Production and Value, YOY Growth
- 5.6.1 North America Cyazofamid Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Cyazofamid Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Cyazofamid Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Cyazofamid Production Value Estimates and Forecasts (2021-2032)
6 Global Cyazofamid Consumption by Region
- 6.1 Global Cyazofamid Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cyazofamid Consumption by Region (2021-2032)
- 6.2.1 Global Cyazofamid Consumption by Region: 2021-2026
- 6.2.2 Global Cyazofamid Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cyazofamid Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Cyazofamid Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Cyazofamid Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Cyazofamid Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Cyazofamid Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Cyazofamid Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Cyazofamid Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Cyazofamid Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Cyazofamid Production by Type (2021-2032)
- 7.1.1 Global Cyazofamid Production by Type (2021-2032) & (kt)
- 7.1.2 Global Cyazofamid Production Market Share by Type (2021-2032)
- 7.2 Global Cyazofamid Production Value by Type (2021-2032)
- 7.2.1 Global Cyazofamid Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Cyazofamid Production Value Market Share by Type (2021-2032)
- 7.3 Global Cyazofamid Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Cyazofamid Production by Application (2021-2032)
- 8.1.1 Global Cyazofamid Production by Application (2021-2032) & (kt)
- 8.1.2 Global Cyazofamid Production Market Share by Application (2021-2032)
- 8.2 Global Cyazofamid Production Value by Application (2021-2032)
- 8.2.1 Global Cyazofamid Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Cyazofamid Production Value Market Share by Application (2021-2032)
- 8.3 Global Cyazofamid Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Cyazofamid Value Chain Analysis
- 9.1.1 Cyazofamid Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Cyazofamid Production Mode & Process
- 9.2 Cyazofamid Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Cyazofamid Distributors
- 9.2.3 Cyazofamid Customers
10 Global Cyazofamid Analyzing Market Dynamics
- 10.1 Cyazofamid Industry Trends
- 10.2 Cyazofamid Industry Drivers
- 10.3 Cyazofamid Industry Opportunities and Challenges
- 10.4 Cyazofamid Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst